clobazam 2.5 MG/ML Oral Suspension [Onfi]
clobazam
RxCUI: 1366196
What the CMS Formulary Data Shows for clobazam 2.5 MG/ML Oral Suspension [Onfi]
Per the CMS 2026 Part D formulary file, clobazam 2.5 MG/ML Oral Suspension [Onfi] (RxNorm concept RXCUI 1366196, generic name clobazam) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.
Real-world access to clobazam 2.5 MG/ML Oral Suspension [Onfi] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 18,477 Part D beneficiaries filled clobazam 2.5 MG/ML Oral Suspension [Onfi] in 2023, with total plan-and-beneficiary spending of $30,689,808 and an average per-beneficiary annual cost of $1,660.97. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry clobazam 2.5 MG/ML Oral Suspension [Onfi] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 2
- Coverage rate
- 0%
- Tier range
- Tier 1, Preferred Generic
- Average tier
- Tier 1, Preferred Generic
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 18,477
- Total spending
- $30,689,808
- Avg per beneficiary
- $1,660.97
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering clobazam 2.5 MG/ML Oral Suspension [Onfi]
2 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | Yes | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | Yes | $34.50 | NY |
Frequently Asked Questions
Is clobazam 2.5 MG/ML Oral Suspension [Onfi] covered by Medicare Part D?
Yes, clobazam 2.5 MG/ML Oral Suspension [Onfi] is covered by 2 Medicare Part D plans (0% of all Part D formularies).
What tier is clobazam 2.5 MG/ML Oral Suspension [Onfi] on Medicare Part D plans?
clobazam 2.5 MG/ML Oral Suspension [Onfi] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.
Does clobazam 2.5 MG/ML Oral Suspension [Onfi] require prior authorization?
100% of Part D formularies require prior authorization for clobazam 2.5 MG/ML Oral Suspension [Onfi]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on clobazam 2.5 MG/ML Oral Suspension [Onfi]?
In 2023, total Medicare Part D spending on clobazam 2.5 MG/ML Oral Suspension [Onfi] was $30,689,808, covering 18,477 beneficiaries. The average spend per beneficiary was $1,660.97.
Read our methodology - how this data is sourced, computed, and verified.